A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BACKGROUND: Metastasis directed therapy (MDT) for patients with oligometastatic disease is associated with improvements in progression free survival (PFS) and overall survival (OS) compared to systemic therapy alone. Additionally, within a prostate-cancer-specific cohort, MDT is able to forestall in...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:BMC Cancer
Κύριοι συγγραφείς: Hasan, Hamza, Deek, Matthew P., Phillips, Ryan, Hobbs, Robert F., Malek, Reem, Radwan, Noura, Kiess, Ana P., Dipasquale, Shirl, Huang, James, Caldwell, Terry, Leitzel, Jessica, Wendler, Danielle, Wang, Hao, Thompson, Elizabeth, Powell, Jonathan, Dudley, Sara, Deville, Curtiland, Greco, Stephen C., Song, Daniel Y., DeWeese, Theodore L., Gorin, Michael A., Rowe, Steven P., Denmeade, Sam, Markowski, Mark, Antonarakis, Emmanuel S., Carducci, Michael A., Eisenberger, Mario A., Pomper, Martin G., Pienta, Kenneth J., Paller, Channing J., Tran, Phuoc T.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: BioMed Central 2020
Θέματα:
Study Protocol
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7268477/
https://ncbi.nlm.nih.gov/pubmed/32487038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07000-2
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια